128577-47-9

Basic information

• Product Name: 4-BROMOMETHYL-3-FLUOROBENZOIC ACID METHYL ESTER
• Synonyms: 4-BROMOMETHYL-3-FLUOROBENZOIC ACID METHYL ESTER;MMETHYL 4-(BROMOMETHYL)-3-FLUOROBENZOATE;4-(bromomethyl)-3-fluorobenzoic acid;Methyl 4-broMoMethyl-3-fluorobenzoate;Methyl 4-bromomethyl-3-fluorobenzoat;-3-fluorobenzoate;4-BROMOMETHYL-3-FLUOROBENZOIC ACID METHYL
• CAS NO: 128577-47-9
• Molecular Formula: C₉H₈BrFO₂
• Molecular Weight: 247.06
• EINECS: 604-604-1
• Mol File: 128577-47-9.mol

Chemical Properties

• Melting Point: 68 °C(Solv: ethyl ether (60-29-7); hexane (110-54-3))
• Boiling Point: 295.113 °C at 760 mmHg
• Flash Point: 132.28 °C
• Appearance: /
• Density: 1.534 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.542
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-BROMOMETHYL-3-FLUOROBENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMOMETHYL-3-FLUOROBENZOIC ACID METHYL ESTER(128577-47-9)
• EPA Substance Registry System: 4-BROMOMETHYL-3-FLUOROBENZOIC ACID METHYL ESTER(128577-47-9)

Safety Data

• Hazardous Substances Data: 128577-47-9(Hazardous Substances Data)

Usage

Uses

Methyl 4-(bromomethyl)-3-fluorobenzoate

InChI:InChI=1/C9H8BrFO2/c1-13-9(12)6-2-3-7(5-10)8(11)4-6/h2-4H,5H2,1H3

Upstream product

• 937636-18-5 methyl 3-fluoro-4-(hydroxymethyl)benzoate 
• 1008517-99-4 methyl 4-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-fluorobenzoate 
• 930785-23-2 (4-bromo-2-fluorophenyl)methoxy-tert-butyldimethylsilane 
• 188582-62-9 4-bromo-2-fluorobenzyl alcohol 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 87808-48-8 methyl 3-fluoro-4-methylbenzoate 
• 350-28-7 3-fluoro-4-methyl-benzoic acid 
• 56-23-5 tetrachloromethane 
• 123-56-8 Succinimide 

Downstream Products

• 133052-41-2 4-[(2-butyl-1H-benzimidazol-1-yl)methyl]-3-fluorobenzoic acid 
• 1382991-45-8 3-fluoro-4-(3-fluorobenzyl)benzoic acid 
• 193290-36-7 methyl 4-(cyanomethyl)-3-fluorobenzoate 
• 1324010-24-3 3-fluoro-4-(7-hydroxy-4-oxo-2-(trifluoromethyl)-4H-chromen-3-yl)benzoic acid 
• 1324010-25-4 methyl 3-fluoro-4-(7-hydroxy-4-oxo-2-(trifluoromethyl)-4H-chromen-3-yl)benzoate 

Relevant articles and documents

Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model

Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of neurodegenerative disorders. SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and sel

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease

We have identified chemical probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference versus class I HDACs) to decipher the contribution of HDAC isoforms to the positive impact of dua

1,3,4-OXADIAZOLE AMIDE DERIVATIVE COMPOUND AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.

TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS

Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, tr

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS

The present invention is directed to dihydropyrazolopyrimidinonecompounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Synthesis of novel 3-substituted benzamides related to imatinib

Twelve new 3-substituted benzamide derivatives structurally related to tyrosine kinase inhibitor imatinib have been synthesised by a Cu(I)-catalysed coupling of three previously synthesised (5-iodo-2-methylphenyl)-[4-(pyridin-3-yl)-6-perfluoroalkylpyrimidin-2-yl]amines with four synthesised 3-substituted 4-(4-methylpiperazin-1-ylmethyl)benzamides.

Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with Positron Emission Tomography

Increased activity of efflux transporters, e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), at the blood-brain barrier is a pathological hallmark of many neurological diseases, and the resulting multiple drug resistance represents a major clinical challenge. Noninvasive imaging of transporter activity can help to clarify the underlying mechanisms of drug resistance and facilitate diagnosis, patient stratification, and treatment monitoring. We have developed a metabolically activated radiotracer for functional imaging of P-gp/BCRP activity with positron emission tomography (PET). In preclinical studies, the tracer showed excellent initial brain uptake and clean conversion to the desired metabolite, although at a sluggish rate. Blocking with P-gp/BCRP modulators led to increased levels of brain radioactivity; however, dynamic PET did not show differential clearance rates between treatment and control groups. Our results provide proof-of-concept for development of prodrug tracers for imaging of P-gp/BCRP function in vivo but also highlight some challenges associated with this strategy.

PROTEIN KINASE INHIBITORS

The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.